JP6704411B2 - キメラタンパク質 - Google Patents

キメラタンパク質 Download PDF

Info

Publication number
JP6704411B2
JP6704411B2 JP2017553230A JP2017553230A JP6704411B2 JP 6704411 B2 JP6704411 B2 JP 6704411B2 JP 2017553230 A JP2017553230 A JP 2017553230A JP 2017553230 A JP2017553230 A JP 2017553230A JP 6704411 B2 JP6704411 B2 JP 6704411B2
Authority
JP
Japan
Prior art keywords
cells
cell
fas
protein
transmembrane protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017553230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512154A (ja
JP2018512154A5 (https=
Inventor
マーティン プーレ，
マーティン プーレ，
ブライアン フィリップ，
ブライアン フィリップ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2018512154A publication Critical patent/JP2018512154A/ja
Publication of JP2018512154A5 publication Critical patent/JP2018512154A5/ja
Application granted granted Critical
Publication of JP6704411B2 publication Critical patent/JP6704411B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017553230A 2015-04-13 2016-04-12 キメラタンパク質 Expired - Fee Related JP6704411B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506223.5 2015-04-13
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein
PCT/GB2016/051019 WO2016166521A1 (en) 2015-04-13 2016-04-12 Chimeric protein

Publications (3)

Publication Number Publication Date
JP2018512154A JP2018512154A (ja) 2018-05-17
JP2018512154A5 JP2018512154A5 (https=) 2019-02-28
JP6704411B2 true JP6704411B2 (ja) 2020-06-03

Family

ID=53333686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553230A Expired - Fee Related JP6704411B2 (ja) 2015-04-13 2016-04-12 キメラタンパク質

Country Status (10)

Country Link
US (1) US10869911B2 (https=)
EP (1) EP3283526B1 (https=)
JP (1) JP6704411B2 (https=)
CN (1) CN107531804A (https=)
AU (1) AU2016250200B2 (https=)
CA (1) CA2981846A1 (https=)
ES (1) ES2749903T3 (https=)
GB (1) GB201506223D0 (https=)
HK (1) HK1243107B (https=)
WO (1) WO2016166521A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
AU2020388637A1 (en) * 2019-11-21 2022-07-07 Remedium Bio, Inc. Growth factor restoration
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN115397863A (zh) * 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
KR20230016156A (ko) * 2021-07-21 2023-02-01 한국생명공학연구원 신규한 키메릭 항원 수용체 및 이를 발현하는 면역세포
JP2025540894A (ja) * 2022-11-29 2025-12-16 マルコープ・バイオディスカバリーズ・リミテッド 新規ｃｄ２０タンパク質
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914650D0 (en) * 1999-06-24 1999-08-25 Angyogene Pharmaceuticals Ltd Chimeric proteins mediating targeted apoptosis
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
TR201904484T4 (tr) * 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
CA2891764A1 (en) 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
JP2017100947A (ja) * 2014-03-31 2017-06-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Also Published As

Publication number Publication date
CN107531804A (zh) 2018-01-02
AU2016250200B2 (en) 2020-08-13
EP3283526B1 (en) 2019-09-04
US20180169189A1 (en) 2018-06-21
JP2018512154A (ja) 2018-05-17
WO2016166521A1 (en) 2016-10-20
ES2749903T3 (es) 2020-03-24
CA2981846A1 (en) 2016-10-20
AU2016250200A1 (en) 2017-10-26
HK1243107B (en) 2020-05-08
US10869911B2 (en) 2020-12-22
EP3283526A1 (en) 2018-02-21
GB201506223D0 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
JP6704411B2 (ja) キメラタンパク質
US11103532B2 (en) Chimeric protein
JP7082046B2 (ja) 受容体
HK1243107A1 (en) Chimeric protein
JP2017537622A (ja) がんを治療するための方法及び組成物
TWI843716B (zh) hTERT特異性結合分子
CN113195528A (zh) 对ha-1h特异的结合蛋白及其用途
CN117120069A (zh) 针对bob1定向的t细胞受体及其用途
HK1236005B (en) Chimeric protein
HK1236005A1 (en) Chimeric protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200512

R150 Certificate of patent or registration of utility model

Ref document number: 6704411

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees